KT501 / Kali Therapeutics - LARVOL DELTA

A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Kali Therapeutics, Inc. | Not yet recruiting ➔ Recruiting | N=14 ➔ 24

Enrollment change • Enrollment open • First-in-human • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology